Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04436120 · ClinicalTrials.gov registry record · NA
Treatment Resistance Following Anti-cancer Therapies
A NA study, sponsored by Pfizer.
- Terminated
- Registry status
- NA
- Development phase
- 38
- Enrollment target
NCT04436120 is a NA study that was terminated before completion, run by Pfizer. The registered enrollment target is 38 participants.
The verdict
NCT04436120, a NA study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- NA
- Development phase
- 38 participants
- Enrollment target
Study Summary
The TRANSLATE study aims to better understand why tumors become resistant to standard anti-cancer therapies. New tumor biopsy and blood samples are collected after disease progression on standard-of-care anti-cancer treatment and compared to the initial (archival) tumor biopsy sample taken from the same patient. Annotated reports of results from clinical Next Generation Sequencing (NGS) gene panel tests of both tumor and blood are sent directly from the testing lab to the study physician for discussion with the patient during the study. Patients may participate in interventional treatment clinical trials at the same time as participating in the TRANSLATE study. Primary data will be publicly available after the study to support further research.
Interventions
- PROCEDURE De novo tumor tissue biopsy
- PROCEDURE Research blood draws
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2019-02-13 |
| Est. Completion | 2020-12-14 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04436120
The ClinicalTrials.gov registry entry for NCT04436120 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which De novo tumor tissue biopsy is the first listed.
NCT04436120 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04436120 about?
NCT04436120 is a clinical study titled "Treatment Resistance Following Anti-cancer Therapies". The TRANSLATE study aims to better understand why tumors become resistant to standard anti-cancer therapies. New tumor biopsy and blood samples are collected after disease progression on standard-of-care anti-cancer treatment and compared to the initial (archival) tumor biopsy sample taken from the...
What is the current status of trial NCT04436120?
This trial is currently terminated. It is a NA study. The enrollment target is 38 participants. The study started on 2019-02-13. Estimated completion is 2020-12-14.
What interventions are being tested in trial NCT04436120?
The interventions under investigation include: De novo tumor tissue biopsy (PROCEDURE), Research blood draws (PROCEDURE).
Who is sponsoring clinical trial NCT04436120?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.